Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in ...

A phospholipid nanoemulsion–based ocular lubricant applied twice daily is well tolerated, improves the stability of tear film, and alleviates symptoms in patients with dry eye disease. Researchers ...

Detailed price information for Cellectar Biosc (CLRB-Q) from The Globe and Mail including charting and trades.

Invasive plants are doing more than just taking over landscapes—they're also changing the soil beneath them. A new study ...

IT is a disease from the Victorian era but scurvy – caused by vitamin C deficiency – is re-emerging according to doctors. It was rife among seafarers between the 15th and 18th century because they ...

Despite extensive study, the role of PlsX in phospholipid biosynthesis remained an enigma until Lu and coworkers, through the wise use of bioinformatics and the recently released structure of PlsX ...

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim ...

Cellectar’s lead product candidate, iopofosine I 131, is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate. Iopofosine I 131 is an ...

About BXQ-350 Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional, sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 ...

With their unique structure, nanodiscs improve drug delivery and vaccine development, stabilizing membrane proteins for ...

Contrary to popular belief, antioxidants aren’t a panacea. In fact, recent research in Science suggests that for controlling ...